Form 4: Insider Sells MAZE Shares After Option Exercise

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised options and sold a significant number of common shares under a 10b5-1 plan.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., engaged in transactions on March 20, 2026.
• Exercised options to acquire 15,000 shares of common stock at an exercise price of $10.42 per share.
• Subsequently sold a total of 15,000 shares in multiple transactions on the same date.
• The sales occurred at weighted average prices of $48.2027 (for 6,161 shares), $49.3198 (for 3,795 shares), and $50.0186 (for 5,044 shares).
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Bernstein on September 29, 2025.
• Following these transactions, Mr. Bernstein directly owns 0 common shares, but retains 252,407 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event, where an insider monetizes vested options. While a sale, it was pre-planned, mitigating immediate negative sentiment, and the significant profit indicates value creation for the executive.

Positives

• The significant difference between the option exercise price of $10.42 and the sale prices (ranging from $48.20 to $50.02) indicates substantial value creation for the executive through equity compensation.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a structured approach to stock sales rather than an immediate reaction to new, undisclosed information.

Negatives

• An insider selling a substantial number of shares, even under a 10b5-1 plan, could be perceived by some investors as a lack of conviction in the company's near-term stock price appreciation.
• The complete disposal of the 15,000 shares acquired through option exercise means the executive did not increase their direct equity holding from this specific transaction.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports past and planned insider transactions.

Industry Context

StockSavvy.ai notes that insider sales, even under 10b5-1 plans, are common in the biotechnology sector as executives monetize vested equity. The significant spread between exercise and sale price highlights the potential for executive compensation through stock options in successful biotech companies.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of exercising options and immediately selling shares is a standard liquidity event for executives across various industries, particularly in high-growth sectors like biotechnology.
• While specific comparable companies or projects are not detailed in this filing, such transactions are routine for executives at companies like Moderna, BioNTech, or Regeneron, where stock-based compensation forms a significant part of their remuneration.
• The profit margin on the exercised options is substantial, reflecting a successful vesting period for the executive, which is a common outcome for long-tenured executives in successful biotech ventures.

Stakeholder Impact

• Shareholders: May view the insider sale as a signal, though the 10b5-1 plan suggests it's not based on new, undisclosed negative information. The executive's profit highlights the value of equity compensation.
• Employees: No direct impact on employees is mentioned in this transaction report.

Key Dates

Recommendation

The filing details a pre-planned insider transaction, specifically an option exercise followed by a sale, which is a common executive compensation event. It does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment thesis. The transaction was executed under a 10b5-1 plan, suggesting it's not a reaction to new, undisclosed information. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Maze Therapeutics, MAZE, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Harold Bernstein, 10b5-1 Plan, Biotechnology, Pharmaceuticals